2024-09-20 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

1. **Performance vs. S&P 500:** 
    * MRK's cumulative return over the period is 84.71%, while the S&P 500 (VOO) has delivered a cumulative return of 128.99%. 
    * This places MRK's performance **44.28% below the S&P 500**, a relative performance of 38.86% based on historical data.
    * While MRK has underperformed the S&P 500, it's important to consider the historical volatility of the company.

2. **Recent Price Movement:**
    * The closing price for MRK is **$118.65**.
    * The stock is trading slightly above its 5-day moving average of **$117.15** and 20-day moving average of **$116.76**, suggesting a short-term upward trend.
    * However, the stock is below its 60-day moving average of **$120.02**, indicating a longer-term downward trend.

3. **Technical Indicators:**
    * **RSI (Relative Strength Index):** 54.37, indicating the stock is currently in a neutral zone.
    * **PPO (Percentage Price Oscillator):** 0.35, suggesting a slight bullish momentum in the stock.
    * **Delta_Previous_Relative_Divergence:** 4.21, positive value indicates a short-term upward trend in the stock.
    * **Expected_Return:** 13.83%, this represents the potential maximum return over a 5-year period based on current investment levels.

4. **Recent Earnings & Outlook:**
    * MRK's most recent earnings report for the quarter ending 2024-08-05 shows:
        * **EPS:** $2.15
        * **Revenue:** $16.11 Billion
    * This earnings report is **not directly comparable to the previous quarters** due to changes in the company's operations and reporting structures. Therefore, it is difficult to draw definitive conclusions on a trend based solely on these figures.
    * The company's outlook for the future is generally positive, with a strong pipeline of new drugs and vaccines under development. 
    * However, there is potential for challenges in the coming years, including increased competition in the pharmaceutical industry and the potential for regulatory scrutiny.

**Overall Analysis:**

Merck & Co Inc (MRK) is a large pharmaceutical company with a solid track record and a promising future. However, it's currently underperforming the broader market (S&P 500) with a lower cumulative return. 

Short-term technical indicators suggest a potential upward trend, although the long-term trend is currently downward. Recent earnings results are positive, but they are not readily comparable to previous quarters due to changes in the company's operations. Investors should carefully consider the company's outlook, challenges, and competitive landscape before making investment decisions.
